Bristol Myers Squibb (BMS) and Hengrui Pharma have launched a global strategic collaboration and licensing agreement. The partnership encompasses 13 early-stage programs in oncology, hematology, and immunology, with a potential total valuation reaching approximately $15.2 billion.
Collaboration framework and asset distribution The agreement is structured to leverage combined resources for optimizing the experimental drug pipeline:
-
Hengrui-originated assets: BMS receives exclusive worldwide rights (excluding mainland China, Hong Kong, and Macau) for four oncology and hematology programs.
-
BMS-originated assets: Hengrui gains exclusive rights to four immunology programs within the China territory, while BMS retains rights for the rest of the world.
-
Joint discovery programs: Five new projects will be co-developed, utilizing Hengrui’s multi-modality discovery platforms.
Financial and operational advantages BMS has committed to paying Hengrui up to $950 million in near-term cash, including a $600 million upfront payment and two subsequent anniversary payments in 2027 and 2028. Hengrui will oversee early clinical development activities designed to accelerate the generation of proof-of-concept data for the partnered programs.
Strategic vision Leaders from both organizations emphasized the high level of synergy in this deal: BMS provides global regulatory expertise and commercialization infrastructure, while Hengrui contributes an efficient research engine and rapid clinical execution in China. The transaction is expected to close in the third quarter of 2026, setting the stage for long-term growth for both companies over the next decade.